“…Hence, the essential nature and accessibility of the BAM complex makes it a novel and attractive target in today's scenario with widespread antibiotic resistance (Lewis, 2020; Lithgow et al, 2023; Waller et al, 2023). Both natural and synthetic inhibitors of the BAM complex (Overly Cottom et al, 2023) (Table 1 and Figure 6) have recently been tested as potential therapeutics (Di Somma et al, 2022; Ghequire et al, 2018; Hagan et al, 2015; Hart et al, 2019; Imai et al, 2019; Li et al, 2020; Luther et al, 2019; Miller et al, 2022; Overly Cottom et al, 2023; Steenhuis, van Ulsen, et al, 2021; Storek et al, 2018; Urfer et al, 2016; Xu et al, 2023). These target either (Nikaido, 2003) structural components of BamA accessible extracellularly, or (Bos et al, 2007) essential interactions between BAM complex components, such as BamA–BamD interactions (Figures 6 and 7) (Overly Cottom et al, 2023; Srinivas et al, 2010; Xu et al, 2023).…”